180 related articles for article (PubMed ID: 38060834)
1. Identifying Phosphodiesterase-5 Inhibitors with Drug Repurposing Approach: Implications in Vasodysfunctional Disorders.
Khan MS; Mohammad HA; Shahwan M; Yadav DK; Anwar S; Shamsi A
ChemistryOpen; 2024 May; 13(5):e202300196. PubMed ID: 38060834
[TBL] [Abstract][Full Text] [Related]
2. Identification of Potential Inhibitors of PDE5 based on Structure-based Virtual Screening Approaches.
Xu L; Sun L; Su P; Ma T; Yu Y; Liu H; Huang X
Curr Comput Aided Drug Des; 2023; 19(3):234-242. PubMed ID: 36503473
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
4. Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development.
Kayık G; Tüzün NŞ; Durdagi S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):311-330. PubMed ID: 28150511
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity.
Mittal A; Paliwal S; Sharma M; Singh A; Sharma S; Yadav D
Bioorg Med Chem Lett; 2014 Jul; 24(14):3137-41. PubMed ID: 24856068
[TBL] [Abstract][Full Text] [Related]
6. Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.
Liu J; Zhang X; Chen G; Shao Q; Zou Y; Li Z; Su H; Li M; Xu Y
Eur J Med Chem; 2023 Dec; 262():115893. PubMed ID: 37918035
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
[TBL] [Abstract][Full Text] [Related]
8. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
Kayık G; Tüzün NŞ; Durdagi S
J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
[TBL] [Abstract][Full Text] [Related]
9. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
Biswas KH; Visweswariah SS
J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
[TBL] [Abstract][Full Text] [Related]
10. Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach.
Ongaro A; Zagotto G; Memo M; Gianoncelli A; Ribaudo G
Nat Prod Res; 2021 May; 35(10):1648-1653. PubMed ID: 31140295
[TBL] [Abstract][Full Text] [Related]
11. Aphrodisiac Performance of Bioactive Compounds from
Palanichamy C; Pavadai P; Panneerselvam T; Arunachalam S; Babkiewicz E; Ram Kumar Pandian S; Shanmugampillai Jeyarajaguru K; Nayak Ammunje D; Kannan S; Chandrasekaran J; Sundar K; Maszczyk P; Kunjiappan S
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744923
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
[TBL] [Abstract][Full Text] [Related]
13. Coupling of conformational dynamics and inhibitor binding in the phosphodiesterase-5 family.
Tripathi S; Cote RH; Vashisth H
Protein Sci; 2023 Aug; 32(8):e4720. PubMed ID: 37407431
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.
Sawant SD; Lakshma Reddy G; Dar MI; Srinivas M; Gupta G; Sahu PK; Mahajan P; Nargotra A; Singh S; Sharma SC; Tikoo M; Singh G; Vishwakarma RA; Syed SH
Bioorg Med Chem; 2015 May; 23(9):2121-8. PubMed ID: 25801159
[TBL] [Abstract][Full Text] [Related]
15. Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5.
Gong X; Wang G; Ren J; Liu Z; Wang Z; Chen T; Yang X; Jiang X; Shen J; Jiang H; Aisa HA; Xu Y; Li J
Bioorg Med Chem Lett; 2013 Sep; 23(17):4944-7. PubMed ID: 23867165
[TBL] [Abstract][Full Text] [Related]
16. Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Li Y; Wu W; Ren H; Wang J; Zhang S; Li G; Yang L
J Mol Graph Model; 2012 Sep; 38():112-22. PubMed ID: 23085160
[TBL] [Abstract][Full Text] [Related]
17. The GAF-tandem domain of phosphodiesterase 5 as a potential drug target.
Schultz JE; Dunkern T; Gawlitta-Gorka E; Sorg G
Handb Exp Pharmacol; 2011; (204):151-66. PubMed ID: 21695639
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.
Zhang T; Lai Z; Yuan S; Huang YY; Dong G; Sheng C; Ke H; Luo HB
J Med Chem; 2020 Sep; 63(17):9828-9837. PubMed ID: 32794708
[TBL] [Abstract][Full Text] [Related]
19. Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
Abdel-Halim M; Tinsley H; Keeton AB; Weam M; Atta NH; Hammam MA; Hefnawy A; Hartmann RW; Engel M; Piazza GA; Abadi AH
Bioorg Chem; 2020 Nov; 104():104322. PubMed ID: 33142429
[TBL] [Abstract][Full Text] [Related]
20. Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil.
Corbin JD; Foster TL; Bessay E; Busch J; Blount M; Francis SH
Cell Signal; 2011 May; 23(5):778-84. PubMed ID: 21187142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
